Company intelligence / Profile preview

Diffuse Bio

San Francisco, California, United Statesdiffuse.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Diffuse Bio has demonstrated the ability to generate novel proteins with high affinity and specificity using generative AI. Early results include experimental validation of AI-designed proteins, including the first crystal structures of such proteins. No clinical trial data reported yet.[1][2]

Therapeutic areas: Other
Modalities: Protein therapeutics (including VHH nanobodies)Biologics[5][7]
Industry: Biotech

Partnerships

Y Combinator accelerator participant[3](No major pharma/biotech partnerships publicly announced.)

Beyond the preview

Go deeper on Diffuse Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diffuse Bio.

Explore the full profile